Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Beam Therapeutics Inc (Beam Therapeutics) is a biotechnology company that develops precision genetic medicines for serious diseases. The company develops drugs by using base editing technology which includes the REPAIR system for A-to-I (adenosine to inosine) and the RESCUE system for C-to-U (cytosine to uracil) for ribonucleic acid editing. It is developing BEAM-101 and ESCAPE to treat sickle cell disease and beta-thalassemia; BEAM-201, a multiplex base edited anti-CD7 CAR-T cell investigational therapy for T-cell acute lymphoblastic leukemia and acute myeloid leukemia; BEAM-301 targets glycogen storage disease 1a; BEAM-302 is a liver-targeting lipid nanoparticle formulation for alpha-1 antitrypsin deficiency. Beam Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
238 Main Street, Cambridge, Massachusetts, 02142
Website
beamtx.com
Telephone
1 857 3278775
No of Employees
436
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BEAM (NASD)
Revenue (2022)
$377.7M
520%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
54.2%
(2022 vs 2021)
Market Cap*
$2.0B
Net Profit Margin (2022)
XYZ
92.6%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Pipeline | REPAIR |
| BEAM-101: | RESCUE |
| Sickle Cell Disease | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Beam Therapeutics Inc | Bristol-Myers Squibb Co | Gilead Sciences Inc | Vertex Pharmaceuticals Inc | Ultragenyx Pharmaceutical Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | Princeton | Foster City | Boston | Novato |
| State/Province | Massachusetts | New Jersey | California | Massachusetts | California |
| No. of Employees | 436 | 34,100 | 18,000 | 5,400 | 1,276 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John Evans | Director; Chief Executive Officer | Executive Board | 2017 | 45 |
| Terry-Ann Burrell | Treasurer; Chief Financial Officer | Senior Management | 2019 | 46 |
| Manmohan Singh, Ph.D. | Chief Technology Officer | Senior Management | - | - |
| Christine Bellon, Ph.D. | Secretary; Chief Legal Officer | Senior Management | 2019 | 58 |
| Amy Simon, M.D. | Chief Medical Officer | Senior Management | 2021 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer